Shareholdings
Information on shares held by the Shionogi Group and the purpose of the shareholdings are described in “Part I Corporate Information, IV Status of Company, 4. Corporate Governance, (5) Shareholdings” of the Securities Report for the 157th Period (from April 1, 2021 to March 31, 2022).
For your information (in Japanese) : pages 57 to 60 of the Securities Report for the 157th Period(Fiscal Year Ended March 2022).
The English translation of the relevant pages is as follows;
(5) [Status of Shareholding]
(i) Standards and approach toward classification of invested shares
The Group shall only hold shares of companies if management judges that holding the shares will increase the Group’s corporate value and contribute to the sustainable enhancement of corporate value from the two perspectives of economic rationale and strategic validity. Therefore, the Group does not hold shares for passive investment purposes.
(ii) Invested shares held for purposes other than passive investment
a. Shareholding policy and method of verifying rationale of holding, and details of verification by Board of Directors, etc. concerning holding of individual shares
The management of the Group shall judge the appropriateness of holding from the perspectives of economic rationale and strategic validity. Each year, the Board of Directors conducts a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings.
b. Number of stocks (issues) and balance sheet amount
|
No. of stocks (Issues) | Total balance sheet amount (Million yen) |
Unlisted shares |
45 |
9,055 |
Shares other than unlisted shares |
19 |
38,148 |
|
No. of stocks (Issues) |
Total purchase cost for the increase in shares (Million yen) |
Reason for the increase in shares |
Unlisted shares |
5 |
2,113 |
The shares were newly acquired since management judged that holding the shares will increase the Group’s corporate value and contribute to sustainable enhancement of corporate value. |
Shares other than unlisted shares |
- |
- |
|
|
No. of stocks (Issues) | Total sale value for the decrease in shares (Million yen) |
Unlisted shares |
1 |
0 |
Shares other than unlisted shares |
|
|
c. Information on number of shares and balance sheet amount of specified investment shares and deemed holding shares
Stock |
Fiscal year under review |
Previous fiscal year |
Purpose of holding, quantitative effects of holding, and reason for the increase in shares |
Holding of Shionogi shares |
No. of shares |
No. of shares |
|||
Balance sheet amount (Million yen) |
Balance sheet amount (Million yen) |
|||
Suzuken Co., Ltd. |
3,256,696 |
3,256,696 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
Yes |
11,821 |
14,085 |
|||
Toho Holdings Co., Ltd. |
3,500,112 |
3,500,112 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
Yes |
6,475 |
7,105 |
|||
Sumitomo Mitsui Financial Group, Inc. |
1,643,810 |
1,643,810 |
The Shionogi Group holds shares in the company, which is one of the Group’s financial institution, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
6,422 |
6,586 |
|||
StemRim Inc. |
4,650,000 |
4,650,000 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
3,775 |
3,845 |
|||
Medipal Holdings Corporation |
1,271,605 |
1,271,605 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
Yes |
2,562 |
2,700 |
|||
Kissei Pharmaceutical Co., Ltd. |
914,000 |
914,000 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
Yes |
2,335 |
2,239 |
|||
Ono Pharmaceutical Co., Ltd. |
344,095 |
344,095 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
Yes |
1,054 |
994 |
|||
Kaneka Corporation |
266,600 |
266,600 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
Yes |
945 |
1,213 |
|||
OncoTherapy Science, Inc. |
7,300,000 |
7,300,000 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
503 |
897 |
|||
AnGes, Inc. |
1,186,800 |
1,186,800 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
426 |
1,267 |
|||
Sumitomo Mitsui Trust Holdings, Inc. |
105,210 |
105,210 |
The Shionogi Group holds shares in the company, which is one of the Group’s financial institution, to maintain and enhance business relations. In May 2020, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
420 |
406 |
|||
Vital KSK Holdings, Inc. |
475,000 |
475,000 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
349 |
374 |
|||
FunPep Co., Ltd. |
1,095,200 |
1,095,200 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
252 |
519 |
|||
HOKUYAKU TAKEYAMA Holdings, Inc. |
367,530 |
367,530 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
Yes |
242 |
277 |
|||
Nomura Holdings, Inc. |
424,568 |
424,568 |
The Shionogi Group holds shares in the company, which is one of the Group’s financial institution, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
218 |
246 |
|||
Resona Holdings, Inc. |
416,968 |
416,968 |
The Shionogi Group holds shares in the company, which is one of the Group’s financial institution, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
218 |
193 |
|||
MS & AD Insurance Group Holdings, Inc. |
21,811 |
21,811 |
The Shionogi Group holds shares in the company, which is one of the Group’s financial institution, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
86 |
70 |
|||
Senshu Ikeda Holdings, Inc. |
203,725 |
203,725 |
The Shionogi Group holds shares in the company, which is one of the Group’s financial institution, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
35 |
36 |
|||
The Royal Hotel, Ltd. |
654 |
654 |
The Shionogi Group holds shares in the company, which is one of the Group’s business partners, to maintain and enhance business relations. In May 2022, the Board of Directors conducted a comprehensive verification of the purpose, benefits and/or risks associated with holding, capital costs and other aspects regarding individual cross-shareholdings, and confirmed the economic rationale and strategic validity. |
No |
0 |
0 |
Note: The method of verifying the rationale of the holdings is described, since it is difficult to state the quantitative effects of the holding as the transaction amount, etc. are undisclosed information.
(iii) Invested shares held for passive investment purposes
Not applicable.